These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12599519)

  • 1. [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].
    Kondo T; Takubo H; Yokochi F; Okuma Y; Mizuno Y
    No To Shinkei; 2002 Dec; 54(12):1041-8. PubMed ID: 12599519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1994 May; 46(5):465-71. PubMed ID: 8060685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1996 May; 48(5):467-72. PubMed ID: 8672306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms.
    Ondo WG; Sethi KD; Kricorian G
    Clin Neuropharmacol; 2007; 30(5):295-300. PubMed ID: 17909308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term selegiline tolerance in the treatment of Parkinson's disease].
    Vermersch P; Petit H
    Therapie; 1992; 47(1):75-8. PubMed ID: 1523599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
    Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
    J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with selegiline in the treatment of Parkinson's disease.
    Poewe W; Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1987; 25():131-5. PubMed ID: 3123599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
    Lew MF
    Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current controversies in the use of selegiline hydrochloride.
    Lees AJ
    J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-deprenyl therapy in Thai patients with Parkinson's disease: before and after, clinical trial of 50 patients.
    Poungvarin N; Viriyavejakul A
    J Med Assoc Thai; 1990 Jul; 73(7):381-6. PubMed ID: 2123233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline, pregnancy, and Parkinson's disease.
    Kupsch A; Oertel WH
    Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].
    Bettini R; Gorini M
    Clin Ter; 2002; 153(6):377-80. PubMed ID: 12645393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.